Why have it done in China specifically?

China has become a global hub for stem cell therapy due to its advanced regulatory framework for cell-based treatments, lower costs, and high patient volumes. The price of approximately $18,000 for three doses is significantly less than similar therapies in the US or Europe, which can exceed $50,000. Chinese hospitals often have extensive experience treating refractory lupus with MSC infusions, with published clinical data supporting safety and efficacy. Additionally, patients benefit from integrated care teams that include rheumatologists and cell therapy specialists.